HugoHoolMD

Oncology • Torrance, CA

Hematologic Oncology

Director of The Hunt Cancer Institute

Join to view full profile

Dr. Hool is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Hool's full profile

Already have an account?

Office
3285 Skypark Dr
Torrance, CA 90505
Phone+1 310-750-3300

Fax+1 310-750-3381

Education & Training

Olive View/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 2000 - 2003
UCLA-VA Greater Los AngelesResidency, Internal Medicine, 1997 - 2000
Rutgers Robert Wood Johnson Medical SchoolClass of 1997, MD
University of California at IrvineBS, Biology, 1989 - 1991

Certifications & Licensure

CA State Medical License 1998 - 2026
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients Start of enrollment: 2009 Oct 01
Completed
Phase 2
A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer Start of enrollment: 2012 Oct 01
Completed
Phase 1, Phase 2
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Start of enrollment: 2013 Jan 16
Terminated
Phase 3
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Start of enrollment: 2013 Jan 02
Terminated
Phase 3
A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach Start of enrollment: 2013 Jan 01
Terminated
Phase 2
A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC Start of enrollment: 2013 Apr 01
Terminated
Phase 3
A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06) Start of enrollment: 2014 Sep 30
Completed
Phase 3
A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive Label Start of enrollment: 2014 Nov 01
Terminated
Phase 2
A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer Start of enrollment: 2015 May 01
Completed
Phase 2
A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer Start of enrollment: 2015 Jul 13
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

65 citations
A randomized phase II trial of nab‐paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer
Zishuo Ian Hu, Johanna C. Bendell, Andrea J. Bullock, Noelle K. LoConte, Hassan Hatoum
Cancer Medicine. 2019-09-01

Press Mentions

Three Years Later: Torrance Memorial & Cedars-Sinai Collaboration Continues to Bring Advanced Care to the South Bay CommunityNovember 13th, 2021
New Cancer Treatment Center Coming at Torrance Memorial HospitalJuly 16th, 2018
Cedars-Sinai Affiliate Breaks Ground on New Cancer CenterJuly 13th, 2018